Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15115449 | 0.98 | PPARA (0.55) | PPARAPTGS2CYP3A4ELANEGPR84 | |
| SCHEMBL10469446 | 0.98 | PPARA (0.55) | PPARAPTGS2CYP3A4ELANEGPR84 | |
| SCHEMBL9529025 | 0.98 | PPARA (0.55) | PPARAPTGS2CYP3A4ELANEGPR84 | |
| SCHEMBL11933711 | 0.98 | PPARA (0.55) | PPARAPTGS2CYP3A4ELANEGPR84 | |
| SCHEMBL9532366 | 0.98 | PPARA (0.55) | PPARAPTGS2CYP3A4ELANEGPR84 | |
| SCHEMBL10469531 | 0.94 | PPARA (0.46) | PPARAPTGS2CYP3A4ELANENPC1 | |
| SCHEMBL5019886 | 0.86 | — | — | |
| SCHEMBL16276992 | 0.80 | PPARA (0.36) | PPARA | |
| SCHEMBL22098155 | 0.80 | PPARA (0.36) | PPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16277020 | 0.79 | PPARA (0.38) | PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104529925-A | 5-(4-nitrophenyl)-3-hydroxylisoxazole and preparation process and use thereof | WUHAN INST TECHNOLOGY | 2015-04-22 | — | — | CN | claimed |
| EP-4362928-A1 | UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT AND PREVENTION OF AN AMMONIA-ASSOCIATED DISEASE OR DISORDER | Versantis AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023275790-A1 | UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT AND PREVENTION OF AN AMMONIA-ASSOCIATED DISEASE OR DISORDER | ETH ZURICH (CH) | 2023-01-05 | — | — | WO | disclosed |
| US-10159658-B2 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20170165209-A1 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk | ANJI PHARMACEUTICALS INC. | 2017-06-15 | — | — | US | disclosed |
| US-9572784-B2 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150196509-A1 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk | ANJI PHARMACEUTICALS INC. | 2015-07-16 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| WO-2013105061-A1 | FUSED DIHYDROPYRIDO [2,3 -B] PYRAZINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-0994107-A1 | 5-Arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds | H. LUNDBECK A/S (DK) | 2000-04-19 | — | — | EP | disclosed |
| EP-0726896-A1 | 5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS | H. LUNDBECK A/S (DK) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012587-A1 | 5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS | H. LUNDBECK A/S (DK) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10159658-B2 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | PCSK9, HMGCR, PCSK7 | PPARA 241/4885PTGS2 2955/4885CYP3A4 541/4885 |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | PPARA 126/4885PTGS2 4090/4885CYP3A4 2676/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | PPARA 131/4885PTGS2 3728/4885CYP3A4 2460/4885 |
| US-20170165209-A1 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk | PCSK9, HMGCR, PCSK7 | PPARA 241/4885PTGS2 2955/4885CYP3A4 541/4885 |
| US-20150196509-A1 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk | PCSK9, HMGCR, PCSK7 | PPARA 241/4885PTGS2 2955/4885CYP3A4 541/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | PPARA 162/4885PTGS2 3697/4885CYP3A4 1510/4885 |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | GPR119, GPR27, GPR65 | PPARA 123/4885PTGS2 3035/4885CYP3A4 2392/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | PPARA 131/4885PTGS2 3735/4885CYP3A4 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.